Compare Novo Nordisk A/S (NVO) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Royal Bank of Canada — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Royal Bank of Canada trades at $210.37 (market cap $289.51B). The key difference: Royal Bank of Canada is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | RY | |
|---|---|---|
Market Cap | $220.53B | $289.51B |
Sector | Health | Financials |
52-Week High | $71.70 | $217.87 |
52-Week Low | $35.29 | $128.46 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
